Cipla Limited, based in Mumbai, is a leading Indian multinational pharmaceutical company dedicated to developing treatments for a wide range of conditions including respiratory and cardiovascular diseases, arthritis, diabetes, depression, and pediatric care, among others.
Built on the foundation of compassion, Cipla’s core purpose—Caring for Life—has shaped every aspect of the organization. Guided by this mission, Cipla now operates in over 80 countries, offering more than 1,500 products across diverse therapeutic segments and over 50 dosage forms.
With a focus on enhancing global healthcare affordability, Cipla continues to strengthen its presence in critical markets such as India, South Africa, the U.S., and other emerging economies.
For more than 80 years, Cipla’s commitment to patient well-being has been the driving force behind its innovations. A landmark moment came in 2001 when Cipla introduced a triple-drug HIV/AIDS therapy in Africa for under a dollar a day—an initiative that significantly advanced access and affordability in global health.
As a socially responsible company, Cipla blends humanitarian values with its business practices, earning the trust of international health organizations and partners. Its consistent efforts to support communities and deliver inclusive healthcare have made Cipla a preferred ally in advancing public health.
